Reuters exclusively reported that Novo Nordisk has hired Thermo Fisher as its second contract manufacturer for its hugely popular weight-loss drug Wegovy. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but the identity of the company has not previously been reported. This was followed by another exclusive that Catalent’s plant in Bloomington, Indiana, will fill injection pens for Novo Nordisk’s Wegovy as part of the two companies’ expanded supply agreement. Catalent’s shares briefly jumped on the news.
The post Catalent’s Indiana plant to make Novo’s Wegovy weight-loss drug appeared first on Reuters News Agency.
Reuters exclusively reported that India’s pharmaceutical exports this fiscal year are set to grow nearly twice as fast as last year to hit sales of $27 billion, driven by strong U.S. buying, a government-backed trade body told Reuters, despite deaths linked to Indian-made cough syrups.
The post India pharma exports soaring despite cough syrup deaths, trade body says appeared first on Reuters News Agency.
MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition.
Reuters exclusively reported that Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s (NOVOb.CO) Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply.
The post Most patients using weight-loss drugs like Wegovy stop within a year, data show appeared first on Reuters News Agency.
Reuters exclusively reported that one of the world’s most common artificial sweeteners is set to be declared a possible carcinogen next month by a leading global health body, according to two sources with knowledge of the process, pitting it against the food industry and regulators. Aspartame, used in products from Coca-Cola diet sodas to Mars’ Extra chewing gum and some Snapple drinks, will be listed in July as “possibly carcinogenic to humans” for the first time by the International Agency for Research on Cancer (IARC), the World Health Organization’s (WHO) cancer research arm, the sources told Reuters.
The post WHO’s cancer research agency to say aspartame sweetener a possible carcinogen appeared first on Reuters News Agency.